Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients (AVERT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02048865 |
Recruitment Status :
Completed
First Posted : January 29, 2014
Last Update Posted : November 20, 2018
|
Sponsor:
Ottawa Hospital Research Institute
Collaborators:
Canadian Institutes of Health Research (CIHR)
Bristol-Myers Squibb
Information provided by (Responsible Party):
Ottawa Hospital Research Institute
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | October 10, 2018 |
Actual Study Completion Date : | October 19, 2018 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
December 19, 2022 | October 13, 2023 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):